The recent commercial availability of ultrasound contrast agents poses new challenges to ultrasound lprofessionals. There is a need to identify the most:relevant clinical applications for which the agents are indicated, as well as ways jin which to use existing ultrasound technology with contrast. Herein is described la new imaging tehnique frame-one maging that: imp rovsthe detection of contrast in bo0d:tissues. Frame-one imaging was attempted in six examin attons of suspected renal abnormalities performed as part of the FDA Phase IcliIcIal trials of the contrast agent Definity® (DuPont Pharmaceuticals, N. Billerica,: M, A). Conventional and harmonic gray-scale imaging was perfrmed at baseline and postcntrat addm inistration. US imaging results were compared to surgical findings. U1, sing gray-scalle harm: o:nicimagg, improved depiction: of:contrast enhancement was achieved in all:cases where FOI was employed. Contrast enhancement was better demonstrated using the FOI tchnique than with continuous real-time imaging. FOI improved the display of contrast enhancement from within normal tissues and vessels as wel as:frombi tumor vessels and tumor tissue. FOI may permit improved tumor characterization using contrasenhanced sonogphy. Additiol vestigations are neede to determine if FOL can imp0rovethe diagnostic potential of contrast-enhanced sonography.
